Published on : Nov 01, 2016
ALBANY, NY, Nov 01, 2016: The report serves as a repository of analysis and information regarding several aspects of the Asia Pacific gastric cancer therapeutics market, including its dynamics and competitive landscape.
Licensing deals are the most commonly adopted strategy by the leading players to stay relevant in the market. As per the findings of the report, the overall deal values ranged from US$10 mn to over US$200 mn in 2015. The Asia Pacific gastric cancer therapeutics market was valued at US$1.3 bn in 2015 and is expected to rise at a CAGR of 11.4%, reaching US$2.7 bn by 2022.
The survival and life expectancy rate for gastric cancer is largely dependent on the stage of disease and the age of patients. Figures indicate that most of the cases of gastric cancer in the region are diagnosed at a late stage and in patients above the age of 60. As the geriatric population continues to rise, the incidence of gastric cancer is likely to increase. This factor along with the improving healthcare infrastructure is augmenting the growth of the market. Moreover, several government initiatives to curb the spread of cancer are leading to the rise in screening programs, which in turn is working in the favor of the market. Furthermore, the advent of combination therapies and clinical and treatment advancements are driving the growth of the gastric cancer therapeutics market in Asia Pacific.
On the flip side, in the current scenario, while HER2-positive gastric cancer patients get treated with targeted therapies, patients with HER2-negative still get chemotherapy regimens as the first-line treatment. Moreover, patent expiration of blockbuster drugs such as Herceptin is paving way for the increasing adoption of their generic versions, thereby adversely affecting the overall revenue generation of the market. Furthermore, due to their high prices along with constrained healthcare budgets and lack of adequate financial assistance from health insurance policies, the penetration rates of targeted therapies have not reached an optimal level. These factors, collectively, are restraining the growth of the Asia Pacific gastric cancer therapeutics market.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=840987
Nevertheless, the presence of immense unmet needs for the treatment of HER2-negative gastric cancer are likely to open new avenues for companies operating in the market. Moreover, the presence of a promising drug pipeline and the launch of premium-priced drugs for the metastatic setting are likely to create significant growth opportunities for the Asia Pacific gastric cancer therapeutics market.
The report mentions a detailed description of the pipeline products and their expected impact on the market. It analyzes these products on the basis of stage of development, program type, route of administration, and molecule type. It also offers insights into comparative efficacy and safety of the pipeline along with product competitive framework. Some of the promising pipeline candidates covered in the report are Keytruda, Napabucasin, Nimotuzumab, Lynparza, Perjeta, and Opdivo. The report also provides a comprehensive evaluation of the market’s growth across different geographies including China, India, South Korea, Australia, and Japan.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org